Coulie
Bernard Coulie, Herent BE
Patent application number | Description | Published |
---|---|---|
20090048194 | Vagal Afferent Neurons as Targets for Treatment - A method of identifying a compound capable of reducing or preventing prolonged sensory neuron hyper-excitability comprising the steps of: (a) administering the compound to an experimental non-human animal having prolonged sensory neuron hyper-excitability; (b) generating an expression profile of the genes modulated in the Nodose Ganglia (NG) of the animal of step (a); (c) comparing the expression profile obtained in (b) with the expression profile of a corresponding panel of genes expressed in the NG of an experimental non-human animal having no prolonged sensory neuron hyper-excitability; wherein a positive correlation of the expression profiles is indicative that the compound is capable of reducing or preventing prolonged sensory neuron hyper-excitability in NG. | 02-19-2009 |
Pierre Coulie, Brussels BE
Patent application number | Description | Published |
---|---|---|
20090233315 | MAGE-C2 antigenic peptides and uses therefor - This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ∃ | 09-17-2009 |
20110305722 | MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF - This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ∃ | 12-15-2011 |
Pierre G. Coulie, Kraainem BE
Patent application number | Description | Published |
---|---|---|
20100184700 | PREPROCALCITONIN ANTIGEN T EPITOPES - The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy. | 07-22-2010 |